Kimberly Rath, PharmD

BET inhibition in chronic lymphocytic leukemia (CLL) significantly reduces leukemic cell burden and restores T-cell function by modulating the immune microenvironment and reversing T-cell exhaustion.

Recent studies reveal that simoctocog alfa (Nuwiq) offers effective prophylaxis and treatment for severe hemophilia A in children, with low inhibitor rates and strong long-term safety and efficacy.

A case study details the cytological and histological features of fibrin-assisted diffuse large B-cell lymphoma in a patient with no clinical symptoms, highlighting the diagnostic challenges of this condition.

A study found that prehospital blood pressure (BP) reduction had no impact on functional outcomes among patients with undifferentiated acute stroke, but that it may decrease the odds of poor outcomes following hemorrhagic stroke.

Prophylactic intravenous immunoglobulin reduces COVID-19 infection rates in older patients with DLBCL with hypogammaglobulinemia undergoing reduced-intensity R-CHOP therapy.

Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.

Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.

New study findings demonstrate that valoctocogene roxaparvovec, a gene therapy for severe hemophilia A, significantly reduces bleeding episodes and dependency on factor VIII infusions over a 3-year period, while maintaining a favorable safety profile.

This study introduces a novel "all-in-one" strategy combining CD7 chimeric antigen receptor T-cell therapy with haploidentical hematopoietic stem-cell transplantation, showing significant potential to improve survival and reduce toxicities in patients with relapsed or refractory CD7-positive hematologic cancers.

Findings from the FAMS-T1D study demonstrate that structured goal-setting and achievement significantly enhance self-efficacy and self-care in emerging adults who have type 1 diabetes (T1D).

Type 1 diabetes (T1D), which once predominantly affected children, is increasingly affecting older adults in the US, with prevalence rates peaking in those aged 45 to 64, according to recent research.

Data highlight substantial improvements in outcomes following allogeneic hematopoietic cell transplantation (allo-HCT) among older patients with acute myeloid leukemia (AML).

An overview of the treatments for chronic lymphocytic leukemia (CLL) and novel therapies on the horizon, including double and triple combination therapies, cellular therapies, and bispecific antibodies.

UGT2B17, a metabolic enzyme known for regulating various endogenous molecules, has been identified to have heightened expression in the B cells of patients who have chronic lymphocytic leukemia (CLL).

A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.

Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).

Patients with radiographic axial spondyloarthritis (ax-SpA) and a high risk of radiographic progression had similar low progression on both secukinumab and an adalimumab biosimilar.